Cargando…

Structure-based glycoengineering of interferon lambda 4 enhances its productivity and anti-viral potency

Interferon lambda 4 (IFNλ4) has been recently known and studied for its role in hepatitis C virus (HCV) infection, but its clinical potential is significantly hampered due to its poor expression in vitro. Our study reports the successful production of IFNλ4 from a mammalian cell line through a glyco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chung, Jae-Hee, Hong, Seon-Hui, Seo, Nari, Kim, Tae-Shin, An, Hyun Joo, Lee, Pedro, Shin, Eui-Cheol, Kim, Ho Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129780/ https://www.ncbi.nlm.nih.gov/pubmed/31479875 http://dx.doi.org/10.1016/j.cyto.2019.154833

Ejemplares similares

Glycoengineering of Interferon-β 1a Improves Its Biophysical and Pharmacokinetic Properties
por: Song, Kyoung, et al.
Publicado: (2014)

Sensitization of glycoengineered interferon-β1a-resistant cancer cells by cFLIP inhibition for enhanced anti-cancer therapy
por: Kim, Tae-Eun, et al.
Publicado: (2017)

Interferon-inducible protein SCOTIN interferes with HCV replication through the autolysosomal degradation of NS5A
por: Kim, Nari, et al.
Publicado: (2016)

A Glycoengineered Interferon-β Mutein (R27T) Generates Prolonged Signaling by an Altered Receptor-Binding Kinetics
por: Lee, Saehyung, et al.
Publicado: (2019)

Interferon Lambda Genetics and Biology in Regulation of Viral Control
por: Hemann, Emily A., et al.
Publicado: (2017)

The activation of bystander CD8(+) T cells and their roles in viral infection
por: Kim, Tae-Shin, et al.
Publicado: (2019)

The Applications of Metabolic Glycoengineering
por: Ying, Liwei, et al.
Publicado: (2022)

Glycoengineering HIV-1 Env creates ‘supercharged’ and ‘hybrid’ glycans to increase neutralizing antibody potency, breadth and saturation
por: Crooks, Ema T., et al.
Publicado: (2018)

Interferon-Lambda: A Potent Regulator of Intestinal Viral Infections
por: Lee, Sanghyun, et al.
Publicado: (2017)

COVID‐19: lambda interferon against viral load and hyperinflammation
por: Andreakos, Evangelos, et al.
Publicado: (2020)

COVID-19 and emerging viral infections: The case for interferon lambda
por: Prokunina-Olsson, Ludmila, et al.
Publicado: (2020)

Genetic glycoengineering in mammalian cells
por: Narimatsu, Yoshiki, et al.
Publicado: (2021)

Strategies for Glycoengineering Therapeutic Proteins
por: Dammen-Brower, Kris, et al.
Publicado: (2022)

Interferon lambda 4 expression is suppressed by the host during viral infection
por: Hong, MeeAe, et al.
Publicado: (2016)

Type I and III interferon responses in SARS-CoV-2 infection
por: Kim, You-Me, et al.
Publicado: (2021)

The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections
por: Egli, Adrian, et al.
Publicado: (2014)

Cyclopropene derivatives of aminosugars for metabolic glycoengineering
por: Hassenrück, Jessica, et al.
Publicado: (2019)

The influence of interferon-lambda on restricting Middle East Respiratory Syndrome Coronavirus replication in the respiratory epithelium
por: Jeon, Yung Jin, et al.
Publicado: (2020)

Roles of Type I and III Interferons in COVID-19
por: Choi, Hojun, et al.
Publicado: (2021)

Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes
por: Chaturvedi, Nimisha, et al.
Publicado: (2019)

The Key Roles of Interferon Lambda in Human Molecular Defense against Respiratory Viral Infections
por: Lozhkov, Alexey A., et al.
Publicado: (2020)

Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development
por: Li, Wei, et al.
Publicado: (2017)

Direct quality control of glycoengineered erythropoietin variants
por: Čaval, Tomislav, et al.
Publicado: (2018)

Applying Acylated Fucose Analogues to Metabolic Glycoengineering
por: Rosenlöcher, Julia, et al.
Publicado: (2015)

Protein Glycoengineering: An Approach for Improving Protein Properties
por: Ma, Bo, et al.
Publicado: (2020)

Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors
por: Li, Shasha, et al.
Publicado: (2021)

Interferon lambdas: the next cytokine storm
por: Kelly, Christabel, et al.
Publicado: (2011)

Genetics of the Human Interferon Lambda Region
por: Prokunina-Olsson, Ludmila
Publicado: (2019)

Evaluation of the Anti-Viral Activity of Human Recombinant Interferon Lambda-1 against SARS-CoV-2
por: Madonov, P. G., et al.
Publicado: (2021)

The type I interferon response in COVID-19: implications for treatment
por: Lee, Jeong Seok, et al.
Publicado: (2020)

The Allergenic Potency of Japanese Hop Pollen Is Increasing With Environmental Changes in Korea
por: Jin, Hyun Jung, et al.
Publicado: (2013)

Interferon lambda 4 impairs hepatitis C viral antigen presentation and attenuates T cell responses
por: Chen, Qian, et al.
Publicado: (2021)

Genetic variants of interferon lambda-related genes and chronic kidney disease susceptibility in the Korean population
por: Kwak, Jin Ho, et al.
Publicado: (2022)

Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties
por: Luo, Cheng, et al.
Publicado: (2017)

Cytoplasmic glycoengineering enables biosynthesis of nanoscale glycoprotein assemblies
por: Tytgat, Hanne L. P., et al.
Publicado: (2019)

A versatile design platform for glycoengineering therapeutic antibodies
por: Ludwig, Seth D., et al.
Publicado: (2022)

Lambda Interferons: New Cytokines with Old Functions
por: Hamming, Ole J., et al.
Publicado: (2010)

Interferon Lambda: Modulating Immunity in Infectious Diseases
por: Syedbasha, Mohammedyaseen, et al.
Publicado: (2017)

Macrophage Coordination of the Interferon Lambda Immune Response
por: Read, Scott A., et al.
Publicado: (2019)

Interferon Lambda in the Pathogenesis of Inflammatory Bowel Diseases
por: Wallace, Jonathan W., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5v68idlfoungongk315sdgk5mf